Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most hepatotoxicity monitoring and embryo-fetal toxicity guidance is consistent with the label (monthly ALT/AST monitoring prior to initiation and monthly thereafter; discontinue with hepatotoxicity symptoms or bilirubin ≥2×ULN; REMS requirements; pregnancy contraindication). However, several specific statements about monitoring frequency “on a fixed schedule,” “commonly monitored” tests, symptom/to-hold typicality, and “rechecking after holding” are not explicitly supported by the provided label excerpts and reduce alignment.
Category Scores
Accurate Statements
Bosentan can increase liver enzymes.
SECTION 5.1 (Hepatotoxicity) reports ALT/AST and bilirubin elevations in TRACLEER-treated patients.
Liver blood tests are required on a fixed schedule after starting bosentan and during treatment.
SECTION 2.1 states liver aminotransferase levels must be measured prior to initiation and then monthly.
Liver function testing is generally more frequent at the start of bosentan treatment.
SECTION 2.1 requires measurement prior to initiation; (followed by monthly during treatment). Label excerpt supports increased testing immediately before starting rather than explicitly “more frequent at the start” beyond baseline+monthly.
Once stable, liver function monitoring becomes less frequent but ongoing periodic checks are still required.
Not directly supported by provided excerpts; requires monthly measurement per label excerpt, with no “less frequent once stable” stated.
Clinicians monitor liver biochemistry during bosentan treatment.
SECTION 5.2 REMS requires healthcare professionals to review serum aminotransferases (ALT/AST) and bilirubin and agree to order and monitor these tests monthly.
ALT and AST (transaminases) are among the commonly monitored liver tests for patients taking bosentan.
SECTION 2.1 and 5.2 specify measuring liver aminotransferase levels including ALT/AST.
Bilirubin (including total bilirubin) is among the commonly monitored liver tests for patients taking bosentan.
SECTION 5.1 and 5.2 reference bilirubin increases and monitoring; and discontinue threshold uses bilirubin ≥2×ULN.
If liver tests worsen while on bosentan, bosentan is typically held.
SECTION 2.4/5.1: discontinue TRACLEER if aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity or bilirubin ≥2×ULN. The label specifies discontinue rather than explicitly “held,” but this aligns with stopping therapy upon worsening.
Depending on the degree of transaminase or bilirubin rise, the dose may be stopped permanently.
SECTION 2.4 states discontinue TRACLEER if criteria met; and states there is no experience with reintroduction in these circumstances (consistent with permanent discontinuation when criteria met).
The key trigger to hold/adjust bosentan is a rise in transaminases and/or bilirubin compared with baseline.
SECTION 2.4 and 5.1 use criteria for aminotransferase elevations (e.g., thresholds relative to ULN) and bilirubin ≥2×ULN; monitoring is required prior and during treatment.
A baseline liver function test before starting bosentan establishes baseline levels for comparison.
SECTION 2.1 requires measuring liver aminotransferase levels prior to initiation of treatment.
Patients taking bosentan should seek help urgently for symptoms suggesting liver injury, including jaundice.
SECTION 2.4/5.1: discontinue if aminotransferase elevations accompanied by clinical symptoms including jaundice (and other symptoms).
Patients taking bosentan should seek help urgently for symptoms suggesting liver injury, including dark urine or pale stools.
Not explicitly supported by provided excerpts.
Patients taking bosentan should seek help urgently for symptoms suggesting liver injury, including unusual fatigue and severe nausea/vomiting.
SECTION 2.4/5.1 includes nausea, vomiting, unusual lethargy or fatigue as hepatotoxicity clinical symptoms.
Patients taking bosentan should seek help urgently for symptoms suggesting liver injury, including right upper abdominal pain.
SECTION 2.4/5.1 includes abdominal pain as hepatotoxicity clinical symptoms.
Drug interactions (especially with medicines that affect bosentan metabolism) increase the risk of liver enzyme elevations with bosentan.
Not directly supported by the provided excerpts (only cross-reference is mentioned: boxed warning excerpt references see Drug Interactions (7.2), but the actual interactions content is not provided).
Pre-existing liver disease increases the risk of liver enzyme elevations with bosentan.
Not supported by the provided excerpts.
Alcohol use increases the risk of liver enzyme elevations with bosentan.
Not supported by the provided excerpts.
Some interacting medicines can raise bosentan levels or increase liver risk.
Not supported by the provided excerpts.
Some interacting medicines can lead to closer monitoring or avoidance of the combination with bosentan.
Not supported by the provided excerpts.
Higher susceptibility to liver injury increases the risk of liver enzyme elevations with bosentan.
Not supported by the provided excerpts.
After bosentan is held due to worsening liver tests, liver tests are rechecked.
Not supported by the provided excerpts; label excerpt says discontinue and notes no experience with reintroduction, but does not state rechecking schedule after holding.
Some interacting medicines can lead to closer monitoring or avoidance of the combination with bosentan.
Not supported by the provided excerpts.
Unsupported Statements
Once stable, liver function monitoring becomes less frequent but ongoing periodic checks are still required.
Label excerpt provided specifies liver aminotransferase levels must be measured monthly; no reduction in frequency once stable is described in the included text.
Clinicians monitor liver biochemistry during bosentan treatment.
Partially supported via REMS requirements, but the statement is broad; still consistent. (No explicit “clinicians” phrasing needed; monitoring requirement is explicit.)
If liver tests worsen while on bosentan, bosentan is typically held.
Provided label excerpt uses “discontinue,” not “hold.” Severity/threshold-based discontinue is supported; “typically held” phrasing is not exact to label wording.
After bosentan is held due to worsening liver tests, liver tests are rechecked.
No rechecking-after-hold instruction is present in the provided label excerpts.
Drug interactions (especially with medicines that affect bosentan metabolism) increase the risk of liver enzyme elevations with bosentan.
The label excerpts provided do not include actual Drug Interactions (7.2) text or interaction-specific hepatotoxicity risk statements.
Pre-existing liver disease increases the risk of liver enzyme elevations with bosentan.
No liver disease risk statement is present in the provided excerpts.
Alcohol use increases the risk of liver enzyme elevations with bosentan.
No alcohol-related hepatotoxicity risk statement is present in the provided excerpts.
Some interacting medicines can raise bosentan levels or increase liver risk.
No interaction mechanism or hepatotoxicity-risk details are present in the provided excerpts.
Some interacting medicines can lead to closer monitoring or avoidance of the combination with bosentan.
No specific interaction management guidance (monitoring frequency changes/avoidance) is present in the provided excerpts.
Patients taking bosentan should seek help urgently for symptoms suggesting liver injury, including dark urine or pale stools.
Provided excerpts list symptoms such as nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue; dark urine/pale stools are not explicitly mentioned.
Depending on the degree of transaminase or bilirubin rise, the dose may be stopped permanently.
Label excerpt says discontinue TRACLEER if criteria met and there is no experience with reintroduction; it does not frame this as “dose may be stopped permanently” (dose adjustment language not shown). Discontinue criteria are supported, but the phrasing is not exact.
The key trigger to hold/adjust bosentan is a rise in transaminases and/or bilirubin compared with baseline.
Label uses ULN-based thresholds and clinical symptoms; the “compared with baseline” phrasing is not directly stated in the provided excerpts.
Contradictions
Low
AI Statement
Once stable, liver function monitoring becomes less frequent but ongoing periodic checks are still required.
Label Reference
SECTION 2.1: “Measure liver aminotransferase levels prior to initiation of treatment and then monthly.”
Important Omissions
Embryo-fetal toxicity pregnancy-related requirements details beyond contraindication (e.g., contraception timing and pregnancy exclusion; discontinue as soon as possible when pregnancy detected). The provided claims include only that pregnancy is contraindicated implicitly via medication guide/boxed excerpt, but the claim set does not explicitly state the contraception interval or pregnancy-discontinue-as-soon-as-possible guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most safety-relevant hepatotoxicity management points align with label (monthly ALT/AST monitoring; discontinue with hepatotoxicity symptoms or bilirubin ≥2×ULN; include jaundice and lethargy/fatigue symptoms). However, an explicit claim that monitoring becomes less frequent once stable contradicts the label excerpt mandating monthly aminotransferase monitoring. Several interaction/liver disease/alcohol and specific symptom details are unsupported, which could affect correct risk communication/management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
At least one monitoring-frequency claim (“less frequent once stable”) is not supported and conflicts with the provided label excerpt requiring monthly aminotransferase monitoring.
Suggested Improvement
Replace “less frequent once stable” with label-consistent wording (monthly ALT/AST monitoring after baseline). Remove or qualify unsupported interaction/alcohol/liver disease risk statements and symptom specifics not listed (e.g., dark urine/pale stools). When describing discontinuation, use label-consistent “discontinue” language and the bilirubin threshold (≥2×ULN) and symptom list provided.